secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2026-08-04T11:50:16+00:00
Accession:  0001140361-26-031058
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics converts $105.8M debt to equity, eliminating all outstanding notes from Chairman Uihlein
--------------------------------------------------------------------------------

- Converted $91.0M principal + $14.8M accrued interest ($105.8M total) into 34,376,167 shares at ~$3.07 blended price.
- Post-conversion shares outstanding: 100,849,644; Uihlein owns ~44.3% voting power (49.3% including warrants).
- Sixth $10M credit facility (Dec 2025) remains undrawn and available; no notes issued under it.
- Company must register resale of shares within 180 days per registration rights provisions.
- CEO says conversion 'transformative' for balance sheet, strengthens ability to advance belapectin program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/0001140361-26-031058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036126031058/ef20079045_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-031058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer